Njoku Kelechi, Chiasserini Davide, Jones Eleanor R, Barr Chloe E, O'Flynn Helena, Whetton Anthony D, Crosbie Emma J
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, University of Manchester, St. Mary's Hospital, Manchester, United Kingdom.
Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Front Oncol. 2020 Nov 3;10:559016. doi: 10.3389/fonc.2020.559016. eCollection 2020.
Endometrial cancer is the most common malignancy of the female genital tract and its incidence is rising in parallel with the mounting prevalence of obesity. Early diagnosis has great potential to improve outcomes as treatment can be curative, especially for early stage disease. Current tests and procedures for diagnosis are limited by insufficient accuracy in some and unacceptable levels of invasiveness and discomfort in others. There has, therefore, been a growing interest in the search for sensitive and specific biomarkers for endometrial cancer detection based on non-invasive sampling methodologies. Urine, the prototype non-invasive sample, is attractive for biomarker discovery as it is easily accessible and can be collected repeatedly and in quantity. Identification of urinary biomarkers for endometrial cancer detection relies on the excretion of systemic biomarkers by the kidneys or urinary contamination by biomarkers shed from the uterus. In this review, we present the current standing of the search for endometrial cancer urinary biomarkers based on cytology, genomic, transcriptomic, proteomic, and metabolomic platforms. We summarize the biomarker candidates and highlight the challenges inherent in urinary biomarker discovery. We review the various technologies with promise for biomarker detection and assess these novel approaches for endometrial cancer biomarker research.
子宫内膜癌是女性生殖道最常见的恶性肿瘤,其发病率随着肥胖患病率的上升而同步上升。早期诊断对于改善预后具有巨大潜力,因为治疗可能是治愈性的,尤其是对于早期疾病。目前的诊断测试和程序存在局限性,有些准确性不足,有些则具有不可接受的侵入性水平和不适感。因此,基于非侵入性采样方法寻找用于子宫内膜癌检测的敏感和特异性生物标志物的兴趣日益浓厚。尿液作为非侵入性样本的原型,因其易于获取且可反复大量收集,对生物标志物的发现具有吸引力。子宫内膜癌检测的尿液生物标志物的鉴定依赖于肾脏对全身生物标志物的排泄或子宫脱落的生物标志物对尿液的污染。在本综述中,我们介绍了基于细胞学、基因组学、转录组学、蛋白质组学和代谢组学平台寻找子宫内膜癌尿液生物标志物的现状。我们总结了生物标志物候选物,并强调了尿液生物标志物发现中固有的挑战。我们回顾了有希望用于生物标志物检测的各种技术,并评估了这些用于子宫内膜癌生物标志物研究的新方法。